A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Overview

About this study

This study is a double-blind, randomized, placebo-controlled (2:1 niraparib:placebo) study in patients with Stage III or IV ovarian cancer. Patients must have completed front-line platinum based regimen with a physician-assessed response of Complete Response (CR) or Partial Response (PR). Additionally, patients must have a normal or >90% decrease in cancer antigen 125 (CA-125) following front-line platinum treatment. The study will assess the efficacy of niraparib as maintenance treatment, as measured by PFS.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients must be female ≥ 18 years of age, able to understand the study procedures and agree to participate in the study by providing written informed consent.
  • Histological and staging criteria:
    • Patients must have histologically diagnosed high-grade serous or endometrioid, or high-grade predominantly serous or endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that is Stage III or IV according to FIGO criteria.
      • Note: Patients who have received neoadjuvant chemotherapy may be included in the study if post-chemotherapy tumor grade is not evaluable.
  • Surgical criteria:
    • Patients with inoperable Stage III and IV disease are eligible;
    • All Stage IV patients with operable disease are eligible;
    • Patients with stage III or IV disease treated with neoadjuvant chemotherapy and interval debulking surgery are eligible;
    • Patients with stage III disease who have visible residual disease after primary debulking surgery are eligible.
  • Chemotherapy criteria:
    • Patients who have received intraperitoneal chemotherapy are eligible;
    • All patients must have had ≥ 6 and ≤ 9 cycles of platinum-based therapy;
    • Patients must have had ≥ 2 post-operative cycles of platinum-based therapy following interval debulking surgery;
    • Patients must have physician assessed CR or PR after ≥ 3 cycles of therapy;
    • Patients must have either CA-125 in the normal range or CA-125 decrease by more than 90% during their front-line therapy that is stable for at least 7 days (i.e., no increase > 15% from nadir).
  • Patients must be randomized within 12 weeks of the first day of the last cycle of chemotherapy.
  • All patients must agree to undergo central tumor HRD testing.
    • The central HRD test result must be available for randomization as it is a stratification factor. Patients with documented gBRCA1 or gBRCA2 mutation or sBRCA1/2 mutation may be randomized without HRD test results;
    • The tumor sample may be submitted for HRD testing prior to the screening period if it appears the patient is likely to meet other eligibility requirements. Patients are not required to have repeat HRD testing if HRD result is “not determined” (e.g., due to insufficient tumor specimen);
    • Patients with known HRD test results from a commercially available source are allowed to participate in the study; however, they must still agree to submit a tumor sample for central HRD testing. The results of the central HRD testing must be available prior to randomization and must be used for stratification. Additional testing related to HRD may be performed on the sample used for screening and randomization post randomization. If there is inadequate tissue remaining subsequent to the screening analysis, sites may be requested to provide additional tissue from the block used for screening purposes.
  • Patients of childbearing potential must have a negative serum or urine pregnancy test (beta human chorionic gonadotropin [hCG]) within 7 days prior to receiving the first dose of study treatment.
  • Patients must be postmenopausal, free from menses for >1 year, surgically sterilized, or willing to use adequate contraception to prevent pregnancy or must agree to abstain from activities that could result in pregnancy throughout the study, starting with enrollment through180 days after the last dose of study treatment.
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Patients must have adequate organ function, defined as follows (Note: complete blood count [CBC] test should be obtained without transfusion or receipt of stimulating factors within 2 weeks before obtaining screening blood sample):
    • Absolute neutrophil count ≥ 1,500/μL;
    • Platelets ≥ 100,000/μL;
    • Hemoglobin ≥  0 g/dL;
    • Serum creatinine ≤ 1.5 xp peur limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min using hte Cockcroft-Gault equation;
    • Total bilirubin ≤ 1.5 x ULN;
    • Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN.
  • All patients must agree to complete PROs during study and then at 4 weeks, 8 weeks, 12 weeks, and 24 weeks after EOT, regardless of subsequent treatment.
  • Patients must have formalin-fixed, paraffin-embedded tumor samples available from the primary cancer or agree to undergo fresh biopsy prior to study treatment initiation.
  • Patients must be able to take oral medications.

Exclusion Criteria:

  • Patient has mucinous or clear cell subtypes of epithelial ovarian cancer, carcinosarcoma or undifferentiated ovarian cancer.
  • Patients with Stage III disease who have had complete cytoreduction (i.e., no visible residual disease) after primary debulking surgery.
  • Patient has undergone more than two debulking surgeries.
  • Patient is pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and for up to 180 days after the last dose of study treatment.
  • Patient has a known hypersensitivity to the components of niraparib or its excipients.
  • Patient is simultaneously enrolled in any clinical trial of niraparib or any other investigational therapy.
  • Patient has received prior treatment with a known PARP inhibitor or has participated in a study where any treatment arm included administration of a known PARP inhibitor.
  • Patient is to receive bevacizumab as maintenance treatment. Patients who have received bevacizumab with their first-line platinum based therapy but are unable to receive bevacizumab as maintenance therapy due to adverse events or for any other reason are not excluded from study as long as the last dose of bevacizumab was received ≥ 28 days prior to signing the main informed consent form.
  • Patient has had investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study.
  • Patient has had any known ≥ Grade 3 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks.
  • Patient has any known history or current diagnosis of MDS or AML.
  • Patient has undergone major surgery (per Investigator judgment) within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery.
  • Patient has had drainage of ascites within 4 weeks prior to enrollment.
  • Patient has undergone palliative radiotherapy encompassing > 20% of the bone marrow within 1 week of the first dose of study treatment.
  • Patient has a condition (such as transfusion dependent anemia or thrombocytopenia), therapy, or laboratory abnormality that might confound the study results or interfere with the patient’s participation for the full duration of the study treatment, including:
    • Patient received a transfusion (platelets or red blood cells) within 2 weeks of the first dose of study treatment;
    • Patient received colony-stimulating factors (e.g., granulocyte colony stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 2 weeks prior to the first dose of study treatment.
  • Patient is planning to donate blood during the study or for 90 days after the last dose of study treatment.
  • Patient has been diagnosed and/or treated for invasive cancer less than 5 years prior to study enrollment.
    • Note: Patients with definitively treated uterine cervical or urinary tract carcinoma in situ, non-melanomatous skin cancer or ductal carcinoma in situ (DCIS) of the breast are not excluded.
  • Patient has known brain or leptomeningeal metastases that are untreated or uncontrolled (i.e., new or worsening symptom or signs, or unstable steroid requirements).
    • Note: A scan to confirm the absence of brain metastases is not required. Patients with spinal cord compression may be considered if they have received definitive treatment for this and demonstrate evidence of clinically stable disease for 28 days.
  • Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection.
  • Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.
  • Patient is immunocompromised (patients with splenectomy are allowed).
  • Patient has known, active hepatic disease (i.e., hepatitis B or C).
  • Patient has a corrected QT interval (QTc) prolongation > 480 milliseconds at screening.
  • If a patient has a prolonged QTc interval and the prolongation is deemed to be due to a pacemaker upon Investigator evaluation (i.e., the patient otherwise has no cardiac abnormalities), then the patient may be eligible to participate in the study following discussion with the Medical Monitor.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Gerardo Colon-Otero, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

  • Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients with recurrent ovarian cancer after platinum-based chemotherapy, regardless of the presence or absence of mutations. The efficacy of niraparib in patients with newly diagnosed advanced ovarian cancer after a response to first-line platinum-based chemotherapy is unknown. Read More on PubMed
.
CLS-20323755

Mayo Clinic Footer